period.
(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:
(b) Structural optimization and other special charges represent the costs associated with:
(c) Goodwill and other impairments represent the costs associated with:
(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device
reporting regulations and other requirements of the new medical device regulations in the European Union.
(e)  Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to
resolve certain recall-related matters.
(f)  Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to
resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g)    Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:
FINANCIAL CONDITION AND LIQUIDITY
Operating Activities
Cash
provided
by
operating activities was
$250
and
$204
in the
three months
2025
and
2024
. The
increase
was primarily due to
higher net earnings partially offset by the timing of payments and
collections in working capital accounts.
Investing Activities
Cash
used
in
investing activities was
$4,136
and
$408
in the
three months
2025
and
2024
. The
three months
2025
included
cash paid to acquire Inari and purchases of property, plant and
equipment partially offset by proceeds from the sale of short-term
investments. The
three months
2024
included cash paid for the
Serf acquisition. Refer to Note 7 to our Consolidated Financial
Statements for further information on acquisitions.
Financing Activities
Cash
provided
by
financing activities was
$2,534
in the
three
months
2025
and cash
used
in
financing activities was
$418
in
the
three months
2024
. In
2025
, cash
provided
was primarily
driven by proceeds from the issuance of various senior
unsecured notes as described in Note 8 to our Consolidated
Financial Statements. This was partially offset by dividend
payments and cash paid for taxes on withheld shares. Cash
used
in
2024
was primarily driven by dividend payments
and cash paid
for taxes on withheld shares. We did not repurchase any shares
in the
three months
2025
and
2024
.
Liquidity
Cash, cash equivalents, short-term investments and
marketable
securities
were
$2,409
and
$4,493
on
March 31, 2025
and
December 31, 2024
. Current assets
exceeded
current liabilities
by
$5,093
and
$7,231
on
March 31, 2025
and
December 31,
2024
. We anticipate being able to support our short-term liquidity
and operating needs from a variety of sources including cash
from operations, commercial paper and existing credit lines.
We have raised funds in the capital markets